<DOC>
	<DOCNO>NCT01339156</DOCNO>
	<brief_summary>P3914 pro-drug Naproxen , characterize naproxen ( COX inhibit moiety ) link NO moiety intend treatment pain inflammation . The rationale behind development P3914 maintain analgesic , antipyretic anti-inflammatory activity naproxen enhance GI safety virtue release NO besides major effect blood pressure long-term administration .</brief_summary>
	<brief_title>Study P3914 Evaluate Safety , Tolerability , Food Effect &amp; Pharmacokinetics Healthy Male Subjects Efficacy &amp; Safety P3914 Patients With Acute Dental Pain</brief_title>
	<detailed_description />
	<mesh_term>Toothache</mesh_term>
	<criteria>Part A , Part B Part C 1 . Male subject age 18 45 year ( include ) Body Mass Index 18 25 kg/m2 ( include ) . 2 . Subjects normal health determine personal medical history , clinical examination laboratory examination within clinically acceptable normal range . 3 . Subjects clinically acceptable 12lead electrocardiogram ( ECG ) . 4 . Subjects clinically acceptable XRay chest ( P/A view ) . 5 . Subjects clinically acceptable endoscopy . 6 . Have negative urine screen drug abuse ( include amphetamine , barbiturate , benzodiazepine , marijuana , cocaine , morphine ) . 7 . Have negative alcohol breath test . 8 . Subjects willing adhere protocol requirement provide write informed consent . Part D : Patients acute postoperative dental pain ( least moderate severity score 40 mm VAS ) removal impacted third mandibular molar select study participation , meet follow criterion : 1 . Male patient age 18 60 year ( include ) . 2 . Patients acute postoperative dental pain ( least moderate severity score 40 mm Visual Analogue Scale ) 3 . Patients otherwise normal health determine personal medical history , clinical examination laboratory examination within clinically acceptable normal range . 4 . Patients clinically acceptable 12lead electrocardiogram ( ECG ) . 5 . Patients clinically acceptable chest XRay ( P/A view ) . 6 . Patients clinically acceptable endoscopy . 7 . Have negative urine screen drug abuse ( include amphetamine , barbiturate , benzodiazepine , marijuana , cocaine , morphine ) . 8 . Have negative alcohol breath test . 9 . Patients willing adhere protocol requirement provide write informed consent . Part A , Part B Part C : 1 . Hypersensitivity NSAIDs nitrodonating drug . 2 . History presence significant cardiovascular , pulmonary , hepatic , renal , gastrointestinal , endocrine , immunological , dermatological , neurological psychiatric disease disorder . 3 . Any treatment could bring induction inhibition hepatic microsomal enzyme system within one month study start . 4 . History presence significant gastric and/or duodenal ulceration include last three month gastroduodenal bleed include last six month prior screen visit . 5 . History peptic ulceration significant dyspepsia judge investigator . 6 . Endoscopy find gastric duodenal ulcer baseline . Erosive esophagitis endoscopic appearance constitutes risk subject , include study , judge investigator . 7 . Have positive test Helicobacter pylorus infection . 8 . Orthostatic hypotension systolic blood pressure drop ≥ 25 mm Hg and/or diastolic blood pressure drop ≥ 15 mm Hg within 5 minute stand change supine erect position . 9 . A history renal impairment , glomerular filtration rate ( GFR ) &lt; 60 mL/min , visit 1 , serum creatinine value &gt; 140 mol/L . 10 . Use aspirin , H2 antagonists , antacid , misoprostol , proton pump inhibitor , sucralfate include two week prior screen visit . 11 . Subjects currently take sildenafil , anticoagulant ticlopidine , nitrate , nitrovasodilating drug ( e.g . nitroglycerin , isosorbide dinitrate , isosorbide mononitrate , glycerin trinitrate ) , diuretic ( dose potentially leading volume depletion ) . 12 . Use prescribed medication last two week OTC medicinal product ( include herbal/traditional medicine preparation ) last one week prior initiation study . 13 . History presence significant alcoholism drug abuse past one year . 14 . Positive screen test one : HIV , Hepatitis B Hepatitis C. 15 . History presence smoking use tobacco , pan , gutkha product since last six month . 16 . History presence significant asthma , urticaria allergic reaction . 17 . History presence significant thyroid disease , adrenal dysfunction , organic intracranial lesion pituitary tumour . 18 . Difficulty swallow solid like tablet capsule . 19 . History presence cancer . 20 . Difficulty donate blood . 21 . Major illness three month screen . 22 . Participation drug research study within past three month . 23 . Donation blood past three month screen . For Part D : 1 . Hypersensitivity NSAIDs nitrodonating drug . 2 . History presence significant cardiovascular , pulmonary , hepatic , renal , gastrointestinal , endocrine , immunological , dermatological , neurological psychiatric disease disorder . 3 . Any treatment could bring induction inhibition hepatic microsomal enzyme system within 1 month study start . 4 . History presence significant gastric and/or duodenal ulceration include last three month gastroduodenal bleed include last six month prior screen visit . 5 . History peptic ulceration significant dyspepsia judge investigator . 6 . Endoscopy find gastric duodenal ulcer baseline . Erosive esophagitis endoscopic appearance constitutes risk subject , include study , judge investigator . 7 . Have positive test Helicobacter pylorus infection . 8 . Orthostatic hypotension systolic blood pressure drop ≥ 25 mm Hg and/or diastolic blood pressure drop ≥ 15 mm Hg within 5 minute stand change supine erect position . 9 . A history renal impairment , glomerular filtration rate ( GFR ) &lt; 60 mL/min , visit 1 , serum creatinine value &gt; 140 mol/L . 10 . Use aspirin , H2 antagonists , antacid , misoprostol , proton pump inhibitor , sucralfate include two week prior screen visit . 11 . Patients currently take sildenafil , anticoagulant ticlopidine , nitrate , nitrovasodilating drug ( e.g . nitroglycerin , isosorbide dinitrate , isosorbide mononitrate , glycerin trinitrate ) , diuretic ( dose potentially leading volume depletion ) . 12 . Use analgesic 48 hrs precede day dental surgery except use acetaminophen midnight day surgery . 13 . Patients oral surgery 30 day prestudy visit . 14 . Use prescribed medication last two week OTC medicinal product ( include herbal preparation ) last one week prior initiation study . 15 . History presence significant alcoholism drug abuse past one year . 16 . Positive screen test one : HIV , Hepatitis B Hepatitis C. 17 . History presence smoking use tobacco , pan , gutkha product since last 06 month . 18 . History presence significant asthma , urticaria allergic reaction . 19 . History presence significant thyroid disease , adrenal dysfunction , organic intracranial lesion pituitary tumour . 20 . Difficulty swallow solid like tablet capsule . 21 . History presence cancer . 22 . Difficulty donate blood . 23 . Major illness three month screen . 24 . Participation drug research study within past three month . 25 . Donation blood past three month screen .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Food Effect</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>